000 01355 a2200409 4500
005 20250517212316.0
264 0 _c20191025
008 201910s 0 0 eng d
022 _a2045-7634
024 7 _a10.1002/cam4.1505
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aPataer, Apar
245 0 0 _aMajor pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy.
_h[electronic resource]
260 _bCancer medicine
_c06 2018
300 _a2405-2414 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
650 0 4 _aAdult
650 0 4 _aAged
650 0 4 _aAged, 80 and over
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aLung Neoplasms
_xdrug therapy
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aNeoadjuvant Therapy
_xmethods
650 0 4 _aRad51 Recombinase
_xgenetics
650 0 4 _aSurvival Rate
700 1 _aShao, Ruping
700 1 _aCorrea, Arlene M
700 1 _aBehrens, Carmen
700 1 _aRoth, Jack A
700 1 _aVaporciyan, Ara A
700 1 _aWistuba, Ignacio I
700 1 _aSwisher, Stephen G
773 0 _tCancer medicine
_gvol. 7
_gno. 6
_gp. 2405-2414
856 4 0 _uhttps://doi.org/10.1002/cam4.1505
_zAvailable from publisher's website
999 _c28304739
_d28304739